mifepristone

Acting U.S. Attorney General Todd Blanche told faith leaders he plans to take action to restrict mail-order access to abortion medication, stating his commitment to making the Supreme Court’s Dobbs decision permanent in every state. During a call hosted by the White House Faith Office, Blanche mentioned working with U.S. Health and Human Services, the FDA, and President Donald Trump’s White House team on these goals. These efforts come amid ongoing attempts to restrict access to mifepristone.

Acting U.S. Attorney General Todd Blanche, whose nomination advanced in the Senate, told faith leaders he would restrict mail-order access to abortion medication. He emphasized collaboration with federal agencies to enforce policies aligning with the Supreme Court’s Dobbs decision. The discussion follows ongoing efforts to limit mifepristone access and debates over the Comstock Act’s potential enforcement.

Acting U.S. Attorney General Todd Blanche, whose nomination advanced in the Senate, told faith leaders he would restrict mail-order access to abortion medication to ensure the Supreme Court’s Dobbs decision is enforced nationwide. He stated he is collaborating with Health and Human Services, the FDA, and the White House to implement policies targeting mifepristone, a drug used in early abortions, amid ongoing legal challenges to its mail-order availability.

Acting U.S. Attorney General Todd Blanche, whose nomination advanced in the Senate, told faith leaders he would restrict mail-order access to abortion medication. He is collaborating with U.S. Health and Human Services, FDA, and President Donald Trump's team to make the Dobbs decision permanent. Louisiana sued the FDA over mifepristone's mail-order rule, and anti-abortion groups are pushing to enforce the Comstock Act to block drug mailings.

Acting U.S. Attorney General Todd Blanche pledged to restrict mail-order access to abortion medication during a call with faith leaders, collaborating with federal agencies to enforce the Dobbs decision. He emphasized policies to prevent states from allowing mail-order drugs like mifepristone, which Louisiana is challenging in court.

Acting U.S. Attorney General Todd Blanche stated he will work to restrict mail-order access to abortion medications like mifepristone, collaborating with federal agencies and the White House. His comments follow a Louisiana lawsuit challenging the FDA's 2023 rule allowing mail delivery of the drug, with anti-abortion groups advocating for enforcement of the 1873 Comstock Act to block such access.

Acting U.S. Attorney General Todd Blanche stated he will take action to restrict mail-order access to abortion medication, collaborating with federal agencies to enforce the Dobbs decision. His comments followed a call with faith leaders and coincide with ongoing legal challenges to FDA rules allowing remote dispensing of mifepristone.

Missourians obtaining abortion pills via telehealth from out-of-state providers quadrupled from 880 in 2023 to 3,220 in 2025, according to Guttmacher Institute data. A Jackson County court ruling in June 2025 partially lifted abortion restrictions but did not allow in-state telehealth medication prescriptions, forcing patients to seek care from out-of-state providers.

A 2024 Louisiana law reclassified misoprostol, a drug used to treat postpartum hemorrhages and in medical abortions, as a controlled substance, requiring hospitals to store it securely instead of in emergency carts. This change delays access to the drug during emergencies, increasing risks for patients with conditions like asthma or high blood pressure who rely on misoprostol as their primary hemorrhage treatment option.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, a drug used for early pregnancy termination, were not sufficiently justified. The restrictions, challenged by abortion providers in Kansas, Montana, and Virginia, require special certification for pharmacies and clinicians and risk acknowledgment forms. A similar case in Hawaii had previously reached the same conclusion.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, including special certification for pharmacies and clinicians and risk acknowledgment forms, are unlawful and must be reviewed. The lawsuit was filed by abortion providers in Kansas, Montana, and Virginia, with a similar case in Hawaii also finding the restrictions arbitrary.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, including special certification requirements for prescribers and pharmacies, were not sufficiently justified. The decision follows a lawsuit by abortion providers in Kansas, Montana, and Virginia, who argued the restrictions were excessive and inconsistent with legal requirements.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, an abortion drug, were not sufficiently justified, requiring the agency to reconsider them. The lawsuit, filed by abortion providers in Kansas, Montana, and Virginia, argued the restrictions were excessive and inconsistent with legal requirements. A similar case in Hawaii reached the same conclusion earlier.

A federal judge in Virginia ruled that the FDA's 2023 restrictions on mifepristone, a drug used to terminate early pregnancies, are unlawful due to insufficient justification. The ruling follows similar challenges from abortion providers in Kansas, Montana, and Virginia, who argued the restrictions—requiring special certifications and risk acknowledgment forms—are excessive and medically unnecessary.

A federal judge in Virginia ruled that the FDA's 2023 restrictions on mifepristone, including special certification for pharmacies and risk acknowledgment forms, are unlawful and must be reviewed. The lawsuit, filed by providers in Kansas, Montana, and Virginia, argues the restrictions are excessive and inconsistent with legal requirements.

A federal judge ruled that FDA restrictions on mifepristone, an abortion medication, are arbitrary and capricious, ordering the Trump administration to reconsider the restrictions. The judge affirmed the drug's safety and cited growing barriers to abortion access.

A federal judge ruled that the U.S. Food and Drug Administration’s 2023 restrictions on mifepristone, a drug used to terminate early pregnancies, are unlawful and require review. The restrictions, challenged by abortion providers in Kansas, Montana, and Virginia, include mandatory certification for pharmacies and clinicians and risk acknowledgment forms, which plaintiffs argue are excessive and medically unnecessary.

Louisiana's 2024 law reclassified misoprostol, a critical drug for treating pregnancy-related hemorrhages, as a controlled substance, forcing hospitals to store it securely and increasing treatment delays. The law also reclassified mifepristone as a controlled substance, both of which are used in medication abortions, complicating emergency care for patients with conditions like asthma or high blood pressure.

Louisiana's 2024 law reclassified misoprostol as a controlled substance, requiring it to be stored securely and delaying access during emergencies. This has increased hemorrhage risks for pregnant patients, as misoprostol is a critical, cost-effective drug for treating postpartum hemorrhage and has other reproductive healthcare uses.

Louisiana's 2024 law reclassifying misoprostol as a controlled substance forced hospitals to store it securely, delaying access during emergencies. The drug is critical for treating pregnancy-related hemorrhages but is now harder to retrieve, increasing patient risk. The law also reclassified mifepristone, further complicating reproductive healthcare access.

Medicaid funding for Ohio’s reproductive health clinics, including Planned Parenthood locations, has resumed after a yearlong freeze that halted reimbursements for non-abortion services like STI testing and cancer screenings. Clinic closures in Hamilton and Springfield occurred during the freeze, with a 55% drop in family planning visits, disproportionately affecting communities of color. Telehealth services remain available to address access gaps.

A proposed California bill, AB 2540, would require community colleges with health centers to provide access to abortion pills starting in 2029 if funded, extending a 2019 law for public universities. Supporters argue it addresses access barriers for students, while campus health directors express concerns about funding and capacity.

A California bill would require community colleges with health centers to provide medication abortion starting in 2029 if the Legislature provides funding. The bill, AB 2540, follows a 2019 law for universities and aims to address access barriers, but health center directors note staffing and infrastructure challenges.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications and limit minors' access to sexual and reproductive healthcare, including the HPV vaccine. A federal lawsuit challenges FDA rules allowing mifepristone to be dispensed via telehealth, with nationwide implications.

Planned Parenthood expanded medication abortion access in Missouri starting June 22, following a court ruling that struck down state laws restricting abortion care. The Gladstone clinic in Kansas City's Northland became the fourth Missouri location offering medication abortion, with appointments filling quickly due to the new availability.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications and HPV vaccines for minors, effective July 1. The laws require in-person dispensing of abortion pills and prohibit minors under 18 from consenting to STD-related vaccinations in Iowa. A federal lawsuit challenges FDA rules allowing telehealth dispensing of mifepristone, which could impact nationwide access.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications like mifepristone and misoprostol and limit minors' access to the HPV vaccine. A federal lawsuit challenges FDA rules allowing telehealth dispensing of mifepristone, with nationwide implications.

California is challenging claims by Heartbeat International and RealOptions Inc. that a progesterone-based treatment can reverse the effects of the abortion drug mifepristone. A trial in Alameda County Superior Court heard testimony from Dr. Mitchell Creinin, who stated there is no scientific evidence supporting the safety or efficacy of the abortion pill reversal protocol. The state seeks to stop the organizations from making false claims and impose fines.

A pro-life group reported that nearly 330,000 abortion pills were shipped to states with abortion restrictions between July 2023 and December 2025 via blue state shield laws, which protect out-of-state providers from prosecution. The report cites data showing monthly shipments nearly tripled during this period, with 15,000 pills sent monthly to conservative states.

A pro-life group reported that nearly 330,000 abortion pills were shipped to states with abortion restrictions between July 2023 and December 2025 under blue state shield laws, which the group claims enabled abortion numbers in conservative states to remain at or above pre-Dobbs levels. The report cites data showing monthly shipments nearly tripled during this period, from 5,400 pills in July 2023 to 14,870 in December 2025.

Telehealth providers report that banning mifepristone, a key abortion pill, has not halted access as patients continue to receive misoprostol, the other drug used in medication abortions. Legal battles over mailing abortion pills persist, but experts argue widespread knowledge and distribution make restrictions ineffective.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify mifepristone, an abortion medication, as a water contaminant. Environmental experts and the Center for Biological Diversity state there is no evidence of harm from mifepristone in water systems, citing a 1996 FDA statement and common drug trace amounts in water.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify mifepristone, an abortion medication, as a water contaminant. Environmental experts state there is no evidence that mifepristone in wastewater harms humans or the environment, while the request cites a 1996 FDA statement acknowledging the drug may enter the environment but noting harmful effects are 'not anticipated.'

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify the abortion medication mifepristone as a water contaminant. Environmental experts and advocacy groups state there is no evidence that mifepristone harms water systems or humans, while states have introduced legislation to test for the drug in water.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify the abortion medication mifepristone as a water contaminant, citing a 1996 FDA statement. Environmental experts and the Center for Biological Diversity state there is no evidence mifepristone harms water systems or humans, while state lawmakers in seven states introduced bills addressing medication abortion's environmental impact.

Louisiana is attempting to block nationwide mail distribution of mifepristone, an abortion medication, by citing the Comstock Act. The FDA had allowed mail delivery of the drug since 2023, but Louisiana argues this violates federal law. The Supreme Court recently sent the case back for review after overturning a lower court's halt to distribution.

Fourteen state attorneys general and 19 GOP members of Congress are urging the EPA to regulate mifepristone, an abortion medication, as a water contaminant. Environmental experts state there is no evidence that mifepristone harms water systems, while the request references a 1996 FDA statement acknowledging potential environmental entry but no anticipated harm.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to regulate mifepristone as a water contaminant, citing environmental concerns. Experts and the Center for Biological Diversity state there is no evidence mifepristone harms water systems or humans, while the FDA noted in 1996 that environmental effects were 'not anticipated.'

Fourteen state attorneys general and 19 GOP members of Congress are urging the EPA to classify mifepristone, an abortion medication, as a water contaminant. Environmental experts state there is no evidence mifepristone in wastewater harms humans or the environment.

The Alabama Attorney General's Office threatened legal action against six companies distributing abortion-inducing medication, citing Alabama's near-total abortion ban. The office referenced a controversial study from a conservative think tank and acknowledged the action might inadvertently publicize access points for abortion pills.